Cordyceps Sunshine Biotech Holdings Co., Ltd.
Datakwaliteit: 100%
RAJAF
OTC
Manufacturing
Chemicals
€ 9,18
€ 0,00
(0,00%)
Marktkapitalisatie: 1,02 B
Prijs
€ 9,18
Marktkapitalisatie
1,02 B
Dagbereik
€ 3,01 — € 3,01
52-Weeksbereik
€ 3,01 — € 10,56
Volume
154
Openen € 3,01
50D / 200D Gem.
€ 9,18
0,00% above
50D / 200D Gem.
€ 9,16
0,20% above
Quick Summary
Belangrijkste Punten
Net margin of 93,35% shows strong profitability
Generating 117.315,0 in free cash flow
P/E of 1238,17 — premium valuation
ROIC of 345,70% — excellent capital efficiency
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-29,59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC345,70%
Net Margin93,35%
Op. Margin25,54%
Veiligheid
Debt / Equity
N/A
Current Ratio0,04
Interest Coverage8,49
Waardering
PE (TTM)
1238,17
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDA3615,44
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1238,2 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | 93,4 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -29,59% | Revenue Growth (3Y) | 40,23% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 882.533,0 | Net Income (TTM) | 823.860,0 |
| ROE | N/A | ROA | 20,48% |
| Gross Margin | 86,84% | Operating Margin | 25,54% |
| Net Margin | 93,35% | Free Cash Flow (TTM) | 117.315,0 |
| ROIC | 345,70% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,04 |
| Interest Coverage | 8,49 | Asset Turnover | 0,22 |
| Working Capital | -1,41 M | Tangible Book Value | -182.939 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 1238,17 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 1155,86 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 3615,44 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 0,01% | ||
| Market Cap | 1,02 B | Enterprise Value | 1,02 B |
| Per Share | |||
| EPS (Diluted TTM) | 0,01 | Revenue / Share | 0,01 |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 23,50% | FCF Conversion | 14,24% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2023 | FY2024 | FY2022 |
|---|---|---|---|
| Revenue | 882.533,0 | 1,25 M | 448.785,0 |
| Net Income | 823.860,0 | -226.258,0 | -720.093,0 |
| EPS (Diluted) | 0,01 | 0,00 | -0,01 |
| Gross Profit | 766.387,0 | 533.760,0 | -66.672,0 |
| Operating Income | 225.384,0 | -183.913,0 | -642.702,0 |
| EBITDA | — | — | — |
| R&D Expenses | 118.444,0 | 118.444,0 | 118.444,0 |
| SG&A Expenses | — | — | — |
| D&A | 56.757,0 | — | 168.899,0 |
| Interest Expense | 26.535,0 | — | 71.772,0 |
| Income Tax | -42.221,0 | 34.957,0 | 792,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2023 | FY2024 | FY2022 |
|---|---|---|---|
| Total Assets | 3,42 M | 4,62 M | 2,10 M |
| Total Liabilities | 3,50 M | 5,00 M | 3,06 M |
| Shareholders' Equity | -78.731,0 | -375.543,0 | -951.334,0 |
| Total Debt | 431.079,0 | 431.079,0 | — |
| Cash & Equivalents | 15.278,0 | 37.284,0 | 16.100,0 |
| Current Assets | 330.973,0 | 601.602,0 | 501.552,0 |
| Current Liabilities | 2,93 M | 4,99 M | 2,94 M |
{"event":"ticker_viewed","properties":{"ticker":"RAJAF","listing_kind":"stock","pathname":"/stocks/rajaf","exchange":"OTC","country":"US"}}